Clinical trial
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
NCT04459715 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 7, 2020
- Completion date
- September 18, 2024
- Enrollment
- 730 (actual)
- Sites
- 288
Conditions
As the registry lists them; a condition with its own page is linked.
squamous cell carcinoma of the head and neck